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Background: Early life exposure to arsenic is associated with decreased birth weight in highly exposed populations
but little is known about effects of low-level arsenic exposure on growth in utero.
Methods: Using a sample of 272 pregnancies from New Hampshire we obtained biometric measurements directly
from fetal ultrasound reports commonly found in electronic medical records. We used information extraction methods
to develop and validate an automated approach for mining biometric measurements from the text of clinical reports.
As a preliminary analysis, we examined associations between in utero low-level arsenic exposure (as measured by
maternal urinary arsenic concentration) and fetal growth measures (converted to Z-scores based on reference
populations for estimated fetal weight, head, and other body measures) at approximately 18 weeks of gestation.
Results: In a preliminary cross-sectional analysis of 223 out of 272 pregnancies, maternal urinary arsenic concentration
(excluding arsenobetaine) was associated with a reduction in head circumference Z-score (Spearman correlation
coefficient, rs = -0.08, p-value = 0.21) and a stronger association was observed among female fetuses at approximately
18 weeks of gestation (rs = - 0.21, p-value < 0.05). Although, associations were attenuated in adjusted analyses —
among female fetuses a 1 μg/L increase in maternal urinary arsenic concentration was associated with a decrease
of 0.047 (95% CI: -0.115, 0.021) in head circumference and 0.072 (95% CI: −0.151, 0.007) decrease in biparietal head
diameter Z-score.
Conclusions: Our study demonstrates that useful data can be extracted directly from electronic medical records
for epidemiologic research. We also found evidence that exposure to low-level arsenic may be associated with
reduced head circumference in a sex dependent manner that warrants further investigation.
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Arsenic is a metalloid found throughout the world and
human exposure through ingestion of contaminated
water and food has been associated with a wide array of
health effects [1]. More recently, attention has turned to
examining the effects of early life exposure to arsenic on* Correspondence: Margaret.R.Karagas@Dartmouth.edu
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highly exposed populations, early life exposure to arsenic
has been associated with adverse birth outcomes such as
increased risk of infection and diarrheal disease and
higher infant mortality [4-10] as well as childhood neu-
robehavioral effects [3,11-15]. Furthermore, a variety of
health effects have been observed into adulthood result-
ing from early life exposure including higher mortality
rates from bronchiectasis and cancers [16-19], cardiovas-
cular disease [20], and all cause mortality [17].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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and environmental toxicants [2,21-23]. Inorganic arsenic
and its metabolites readily cross the placental barrier
and appear in fetal tissue [24,25]. In animal studies, ar-
senic has been shown to have teratogenic and embryo-
logic toxic effects [26] and research has uncovered
effects on gene expression [27]. While previous studies
have found effects on birth size [7] and growth into
childhood [28] much less is known about effects on
growth in the earliest stages of life [29]. To our knowledge
only one study conducted in a highly exposed population
has examined arsenic’s effects on intrauterine growth and
found growth impairment in a sex-dependent manner
[10]. Due to differences in sociodemographic characteris-
tics and other factors that influence pregnancy, findings
from highly exposed populations are not necessarily
generalizable to other parts of the world with relatively
lower levels of exposure such as the US. One previous
study from Bangladesh found that effects on human
growth may occur at the lower end of the dose response
curve (less than 100 ug/L as measured in urine) suggest-
ing populations experiencing lower levels of exposure may
be affected [7].
Recently investigators are turning to clinical narratives
and free-text reports found in electronic medical records
(EMRs) to extract critical health information that is not
captured in a structured, coded format [30]. In particu-
lar, information extraction techniques are used to obtain
information from unstructured or semi-structured text.
Since the late 1950s obstetrical ultrasound has been used
to inform prenatal care among obstetricians and mid-
wives. Clinically, the fetal ultrasound examination is a
diagnostic procedure used for evaluating fetal weight and
growth, estimating gestational age, and for examining
organ function. At approximately 18 weeks of gestation
the fetus is large enough to obtain accurate assessments
of growth and development. Because of the highly
structured (and consistent) format of the text generally
found in radiological and imaging reports, fetal ultra-
sound reports are excellent candidates for automated
information extraction techniques.
Therefore in a sample of 272 pregnancies from New
Hampshire we sought to extract biometric measure-
ments directly from fetal ultrasound reports found in
EMRs. To demonstrate the utility of automated tech-
niques for epidemiologic study, we also performed a pre-
liminary analysis to examine the relationship between in
utero exposure to low levels of arsenic and fetal growth.
Methods
Study population
The New Hampshire Birth Cohort Study (NHBCS) is an
ongoing prospective study that began in 2009 and cur-
rently includes over 1,000 women from New Hampshire,between the ages 18 and 45 years, with a singleton preg-
nancy and who report having a private well as their pri-
mary home water source. During enrollment at a study
clinic (typically at 24-28 weeks of gestation), study par-
ticipants provide a spot urine sample and complete a
prenatal questionnaire that collects information about
their health and pregnancy. Among a variety of environ-
mental exposures, the NHBCS is particularly focused on
health outcomes associated with low level arsenic expos-
ure, which is common among those in New Hampshire
who consume water from unregulated well water. In this
study population well water total arsenic concentration
was less than 10 μg/L (ranged from 0.0 to 9.3 μg/L) for
all study participants.
Study participants are asked for permission to review
medical record review to gather additional information
about the pregnancy and birth outcomes. For the 272 study
participants who received medical care at Dartmouth
Hitchcock Medical Center in Lebanon, New Hampshire,
and gave permission for the medical record review, we
identified 244 study participants who had at least one
fetal ultrasound examination between 18 and 22 weeks
of gestation, the recommended initial morphologic
ultrasound exam to assess development, that included
fetal growth measurements (Figure 1) [31].
The study protocol for the NHBCS was approved by
the Committee for the Protection of Human Subjects at
Dartmouth College. All study participants provided writ-
ten informed consent.
Fetal biometric measurements from clinical ultrasound
reports
It is common for pregnant women in the US to undergo
at least one fetal ultrasound examination between 18
and 22 weeks of gestation. Morphologic fetal assessment
during an ultrasound examination records biometric
measurements including head circumference (HC),
biparietal diameter (BPD), abdominal circumference
(AC), and femur length (FL). At Dartmouth Hitchcock
Medical Center, BPD is measured from outer to inner
portions of the calvarial wall of the skull, and other mea-
surements including HC, FL, and AC are all measured
from outer to outer portions of the respective anatomy
by trained sonographers. From HC, AC and FL biometric
measurements, we estimated fetal weight (EFW) using the
Hadlock III equation: log10EFW= 1.326 – (0.00326 × AC ×
FL) + (0.0107 × HC) + (0.0438 × AC) + (0.158 × FL) [32].
Fetal ultrasound examinations at Dartmouth Hitchcock
Medical Center are performed on either a General
Electric Voluson (General Electric Healthcare Corpor-
ate Headquarters, Little Chalfont, Buckinghamshire,
UK) or a Phillips iU22 (Philips Healthcare, Andover,
Massachusetts, USA).
Figure 1 Flow diagram of study participant inclusion for extraction
of fetal biometric measurements from ultrasound reports.
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medical Informatics, we queried the EMRs of NHBCS
participants who received prenatal care at Dartmouth
Hitchcock Medical Center and who gave permission to
have their medical records reviewed for current proced-
ural terminology (CPT) codes for ultrasound examinationsTable 1 Ultrasound reports according to current procedural t
CPT code Descrip
76816 Ultrasound pregnant uteru
76805 Ultrasound pregnant uterus, fet
76811 Ultrasound pregnant uterus, fetal an
59000 Ultrasound pregnant uterus
76815 Ultrasound pregnant uter
76812 Ultrasound pregnant uterus, ta
76801 Ultrasound pregnant uteru
Total
Abbreviations: CPT, current procedural terminology.including: 59000, 76801, 76805, 76811, 76812, 76815,
76816, 76817, 76819, and 76820 by cross-linking study
participants’ identification number with their medical rec-
ord number. After removing ultrasound reports that did
not include biometric measurements and mothers who
did not have at least one ultrasound exam between 18 and
22 weeks of gestation, we identified a total of 493 ultra-
sound reports (Figure 1 and Table 1).
While most women receive one fetal ultrasound exam-
ination during their pregnancy, women who at higher
risk for adverse birth outcomes or those who are experi-
encing complications may receive repeated fetal ultra-
sound examinations throughout pregnancy. Among the
ultrasound reports we identified, 42.6% of our sample of
ultrasound reports were for CPT code 76805 which cor-
responds to an initial fetal ultrasound examination,
“Ultrasound pregnant uterus, fetal and maternal evalu-
ation,” and 47.3% for CPT code 76816 that corresponds
to a follow-up ultrasound, “Ultrasound pregnant uterus,
follow-up evaluation” (Table 1).
An automated technique was developed to extract bio-
metric measurements directly from the text of clinical
ultrasound reports obtained from study participants’
EMRs. All ultrasound reports were reposited in a struc-
tural query language (SQL) relational database allowing
us to assign a collection of fetal ultrasound reports to a
specific NHBCS participant. Fetal ultrasound reports ob-
tained from EMRs were in a narrative form consisting of
approximately 100 to 150 lines stored as text strings.
The narrative was separated into “Patient information,”
“Performed by,” “Procedures,” “Indications,” “Fetal evalu-
ation,” “Biometry,” “Gestational age,” “Anatomy,” and “Im-
pression” sections. We focused our attention on the section
reporting biometric measurements within each report
(Figure 2A).
Using information extraction techniques with regular ex-
pressions, an automated method to search the text was de-
veloped (i.e. each text string in each ultrasound report) to
find sections that began with either “BPD:,” “HC:,” “AC:,”
or “FL:.” For sections that began with these prefixes the
program located the character “.”, concatenated characterserminology code.
tion n (%)
s, follow-up evaluation 233 (47.3)
al and maternal evaluation 210 (42.6)
d maternal targeted evaluation 38 (7.7)
, guided amniocentesis 6 (1.2)
us, limited evaluation 3 (0.6)
rgeted evaluation multiple 2 (0.4)
s, nuchal translucency 1 (0.2)
: 493 (100.0)
A B
Figure 2 Example section of ultrasound report that includes fetal biometric measurements (A) and pseudocode used to extract
measurements (B).
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assigned this value to the respective biometric measure-
ment (Figure 2B). After the initial extraction of biometric
measurements from all ultrasound reports, text strings
were converted to numeric variable formats and merged
with other data obtained by the NHBCS.
To assess the accuracy of the automated tool, one mem-
ber of the study staff of the NHBCS reviewed a random
sample of 50 total fetal ultrasound reports. For each re-
port, the staff member manually recorded HC, BPD, AC,
and FL and compared the measurements to those our tool
extracted. Based on this review, the recall (i.e., sensitivity)
and precision (i.e., positive predictive value) of our tool
were both 100% for the set of 200 (four measurements per
report) biometric measurements.
Arsenic exposure assessment
We used maternal urinary arsenic concentrations ob-
tained at approximately 24-28 weeks of gestation as our
measure of in utero arsenic exposure. Spot urine sam-
ples were stored frozen at -20°C or lower until analysis
at the University of Arizona. Samples were analyzed for
individual species of arsenic using a combination of high
performance liquid chromatography (HPLC) and induct-
ively coupled plasma mass spectrometry (ICPMS) that is
able to detect five arsenic species, including arsenate, ar-
senite, monomethylarsonic acid (MMA), dimethylarsinic
acid (DMA), and arsenobetaine [33]. Detection limits for
the five individual arsenic species ranged from 0.10 to0.15 μg/L. The total number of samples below the detec-
tion limit were 160 (71.7%), 100 (44.8%), 4 (1.8%), and 0
(0.0%) for arsenate, arsenite, MMA, and DMA respect-
ively. Samples below the detection limit were assigned a
value equal to the detection limit divided by 2. Unme-
tabolized arsenobetaine is believed to be essentially non-
toxic, therefore we estimated total arsenic by summing
arsenate, arsenite, MMA, and DMA [34,35].
Metabolism of inorganic arsenic differs among individ-
uals and the relative concentration of urinary arsenic
species can used to estimate arsenic methylation cap-
acity [36]. Therefore, we examined maternal arsenic
metabolism (as measured by relative urinary arsenic spe-
cies) as a potential effect modifier of in utero arsenic ex-
posure and fetal growth. To do so, we used the ratio of
MMA to inorganic arsenic (the sum of arsenate and ar-
senite) as a measure of efficiency for the 1st methylation
step and the ratio of DMA to MMA for the 2nd methyla-
tion step of arsenic metabolism. For both ratios we iden-
tified mothers above and below the median to estimate
mothers who exhibited higher versus lower arsenic meta-
bolic efficiency.
Other measures
We examined a variety of factors related to the mother
and fetus as potential covariates in our analyses that were
collected from a combination of a prenatal questionnaire
and medical record review. Maternal factors included age
upon study enrollment, pre-pregnancy body mass index
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ity and we also examined fetal sex.
Gestational age was used to determine age-specific Z-
scores for growth measures and was estimated in two
ways in our data. We used the self-reported last men-
strual period (LMP) for the 133 study participants whose
estimates of gestational age were confirmed with the
fetal ultrasound exam. For 90 study participants (26 of
which had no known LMP and 64 who’s LMP did not
align with dating from fetal ultrasound exam) gestational
age was determine by fetal ultrasound.
To account for differences in maternal urinary dilu-
tion, Cayman’s Creatinine Assay Kit (Cayman Chemical
Company, Ann Arbor, Michigan, USA) was used to de-
termine urinary creatinine.
Statistical analyses
For each of the 223 mothers with urinary arsenic con-
centration measured, one fetal ultrasound examination
with complete fetal biometric measurements was
assigned between the 18 and 22 weeks of gestation. Six-
teen out of the 223 women had more than fetal ultra-
sound with biometric measurements during this window
and for these mothers the ultrasound examination clos-
est to the median (18.4 weeks) was assigned.
For all analyses, biometric measurements from ultra-
sound reports (HC, BPD, AC, and FL) as well as our cal-
culated EFW were converted to age-specific Z-scores.
We explored using reported standard equations from a
variety of reference populations, and based on visual fit
among mothers in the NHBCS (244 pregnancies that had
a total of 493 ultrasound examinations), we chose a refer-
ence population from England for head and body mea-
sures and a reference population from the Netherlands
for EFW (Additional file 1: Figure S1) [37-41]. Use of
the reference distribution from England also allowed us
to compare our results to those of the only other paper
in the literature [10]. For EFW, as reported in the lit-
erature, separate equations were used to estimate age-
specific Z-score before and after 36 weeks of gestation.
We examined relationships between maternal urinary
arsenic concentration and fetal growth in several ways.
We used Spearman correlation to assess crude relation-
ships, LoWeSS (locally weighted scatterplot smoothing)
to visually identify potential non-linear associations, and
linear regression to assess associations adjusted for con-
founding factors. We explored these associations strati-
fied by fetal sex and according to maternal arsenic
metabolism. For all models, associations were based on
an increase of 1 μg/L of maternal total urinary arsenic
concentration. We assessed a variety of maternal and
fetal characteristics as potential covariates in our regres-
sion models (Table 2). Based on these analyses, covari-
ates that effectively changed (operationally defined aschanging the point estimate more than 10% when in-
cluded in the model) estimates of associations in our
cross-sectional analysis were included as covariates for
each respective growth outcome. Although it did not ef-
fectively change our point estimate, we also included
maternal urinary creatinine to account for urinary dilu-
tion in our models. For these models maternal age upon
study enrollment, maternal BMI, parity, and maternal
urinary creatinine were included as continuous variables.
All regression models were based on complete case ana-
lysis for covariates except for urinary creatinine to which
we assigned the 59 mothers with missing values the me-
dian creatinine value (67.7 mg/dL). Statistical analyses
were conducted using Stata MP version 13.1 (StataCorp,
College Station, Texas, USA). We set a p-value for statis-
tical significance to 0.05 (2-sided).
We performed two sensitivity analyses. First, because
for 90 out of 223 study participants, gestational age was
estimated or informed by the actual ultrasound examin-
ation, we examined associations among only those 133
mothers where LMP was used to estimate gestational
age. Second, as 16 out of the 223 mothers had more
than one ultrasound examination (presumably because
they were either higher risk pregnancies or experiencing
complications) we re-examined associations only among
the 207 mothers who had one ultrasound examination.
Results
Study population characteristics
The mean age of women upon study enrollment (between
approximately 24 and 28 weeks of gestation) was 31.7 years
(range 18.5 to 43.4 years) and over 95% were Non-Hispanic
White. The mean pre-pregnancy BMI was 25.9 kg/m2
(range 16.6 to 52.5 kg/m2) and 19 of the 223 study partici-
pants (8.5%) reported smoking during their pregnancy.
Eighty two mothers (36.8%) were primiparous and among
the multiparous mothers, previous live births ranged from
1 to 6 (Table 2). The median maternal total urinary arsenic
concentration (excluding arsenobetaine) obtained between
about 24 and 28 weeks of gestation was 3.1 μg/L (IQR: 1.5
to 5.5 μg/L) and ranged from 0.0 to 22.0 μg/L. Approxi-
mately half of the fetuses were male (51.1%) (Table 2).
At the time of the 18 to 22 week fetal ultrasound
examination, the estimated mean gestational age was
18.4 weeks (range 18.0 to 21.3 weeks). The mean EFW
was calculated to be 244.1 g (SD: 36.4 g). The mean HC,
BPD, AC, and FL obtained directly from ultrasound
examination reports were 156.5 (SD: 8.8), 42.0 (SD: 2.5),
132.8 (SD: 9.3), and 27.9 (SD: 2.1) millimeters respect-
ively. Converted to gestational age specific Z-scores
based on reference population, the mean Z-score for
EFW, HC, BPD, AC, and FL were 0.36 (SD: 1.5), 0.05
(SD: 0.8), -0.92 (SD: 1.00), -0.29 (SD: 0.82), and 0.03 (SD:
0.83) respectively. Across some maternal characteristics
Table 2 Mean Z-score [standard deviation] for fetal biometric measurements at approximately 18 weeks of gestation
according to maternal and fetal characteristics
Head measures Body measures
Variable n (%) Estimated fetal
weight
Head
circumference
Biparietal
diameter
Abdominal
circumference
Femur
length
Maternal characteristics
Age at study enrollment * ** *
<30 years 83 (37.2) 0.21 [1.46] −0.12 [0.82] −1.19 [1.07] −0.30 [0.79] −0.13 [0.85]
≥30 years 140 (62.8) 0.45 [1.46] 0.15 [0.78] −0.75 [0.92] −0.29 [0.83] 0.12 [0.80]
Pre-pregnancy BMI, kg/m2
<25.0, normal 111 (49.8) 0.51 [1.48] 0.13 [0.81] −0.78 [1.08] −0.19 [0.82] 0.06 [0.82]
≥25.0 to < 30.0, overweight 51 (22.9) 0.41 [1.59] 0.10 [0.90] −0.96 [0.96] −0.28 [0.84] 0.64 [0.84]
≥30.0, obese 37 (16.6) −0.06 [1.20] −0.22 [0.66] −1.18 [0.85] −0.49 [0.79] −0.14 [0.70]
unknown 24 (10.8) 0.21 [1.42] −0.03 [0.73] −1.04 [0.86] −0.48 [0.76] 0.08 [1.02]
Smoking during pregnancy
non-smoker 181 (81.2) 0.36 [1.49] 0.05 [0.82] −0.90 [1.04] −0.29 [0.84] 0.04 [0.80]
smoker 19 (8.5) 0.41 [1.28] 0.03 [0.74] −0.96 [0.74] −0.10 [0.58] −0.18 [1.00]
unknown 23 (10.3) 0.28 [1.41] 0.06 [0.75] −1.00 [0.89] −0.45 [0.78] 0.13 [0.92]
Parity **
First live birth 82 (36.8) 0.46 [1.30] 0.14 [0.79] −0.62 [0.90] −0.21 [0.71] 0.05 [0.83]
1 or more live births 136 (61.0) 0.28 [1.54] −0.01 [0.81] −1.09 [0.99] −0.35 [0.86] 0.01 [0.82]
unknown 5 (2.2) 0.83 [1.95] 0.23 [0.94] −1.01 [1.85] −0.02 [1.17] 0.23 [1.06]
Urinary total arsenic
below the median 112 (50.2) 0.28 [1.40] 0.07 [0.76] −0.88 [0.90] −0.33 [0.83] −0.04 [0.77]
above the median 111 (49.8) 0.44 [1.52] 0.86 [0.86] −0.95 [1.09] −0.26 [0.80] 0.09 [0.88]
Fetal characteristics
Sex * ** *
male 114 (51.1) 0.51 [1.35] 0.20 [0.76] −0.69 [0.95] −0.16 [0.76] 0.02 [0.80]
female 101 (45.3) 0.23 [1.53] −0.10 [0.82] −1.13 [0.98] −0.43 [0.84] 0.07 [0.82]
unknown 8 (3.6) −0.19 [1.91] −0.27 [0.91] −1.49 [1.30] −0.43 [1.07] −0.38 [1.23]
Abbreviations: SD, standard deviation; BMI, body mass index.
ANOVA (analysis of variance) used to compare means across categories.
*p-value < 0.05, **p-value < 0.01.
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able, BPD Z-score differed across maternal age categor-
ies, parity, and fetal sex (p-value < 0.001 for all). In
addition, HC Z-score differed across maternal age cat-
egory and fetal sex (p-value < 0.05 for both) and FL Z-
score by maternal age category (p-value < 0.05).
In utero arsenic exposure and fetal growth
In our aggregate, unadjusted analyses using Spearman
correlation we found few apparent associations between
in utero arsenic exposure (measured by maternal urin-
ary arsenic concentration) and EFW, HC, BPD, AC,
and FL Z-scores (Figure 3). However, a slight inverse
association between urinary arsenic concentration and
HC Z-score was seen visually (rs = -0.08, p-value =
0.21). In analyses stratified by fetal sex, we found astatistically significant inverse association between HC
Z-score and urinary arsenic concentration among
female fetuses (rs = - 0.21, p-value < 0.05). This was
observed for BPD Z-score as well, although the associ-
ation did not reach statistical significance (rs = - 0.18, p-
value = 0.08).
In our adjusted linear regression models, we found
only one statistically significant association between
maternal urinary arsenic concentration and fetal
growth measures (Table 3). Although not statistically
significant our findings are suggestive of inverse asso-
ciations between arsenic exposure and head growth
particularly for female fetuses — effect estimates for
HC and BPD Z-score for female fetuses were -0.047
(95% CI: -0.115, 0.021) and -0.072 (95% CI: -0.151,
0.007) respectively.
Figure 3 Unadjusted relationship between maternal total urinary arsenic concentration (excluding arsenobetaine) and estimated fetal
weight (A), head circumference (B), biparietal head diameter (C), abdominal circumference (D), and femur length (E) Z-score. In all panels,
rs represents the Spearman correlation coefficient, black lines represent least squares regression, and dashed line represents LoWeSS (locally
weighted scatterplot smoothing) moving average fitted curve.
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tios of the urinary arsenic metabolites), we found an in-
verse association between BPD Z-score and urinary
arsenic concentration among mothers below the median
for DMA/MMA ratio; a 1 μg/L increase in urinaryarsenic concentration was associated with a 0.010 de-
crease in BPD Z-score (95% CI: -0.193, -0.006). We also
observed inverse associations were for other growth
measures (i.e., with effect estimates ranging from -0.003
to -0.025 for mothers below the median for first step
Table 3 Estimated change in Z-score fetal biometric measurements (95% confidence interval) based on an increase of
1 μg/L of maternal urinary arsenic concentration according to fetal sex and maternal arsenic metabolism
Head measures Body measures
Estimated fetal
weighta
Head
circumferencea
Biparietal
diametera,b
Abdominal
circumferencea,b
Femur
lengthb,c
All −0.003 (-0.061, 0.055) −0.019 (-0.050, 0.013) −0.005 (-0.042, 0.033) 0.006 (-0.027, 0.037) 0.001 (-0.031, 0.033)
By fetal sex
male 0.013 (-0.052, 0.078) −0.016 (-0.052, 0.021) 0.021 (-0.022, 0.065) 0.011 (-0.025, 0.048) 0.014 (-0.023, 0.051)
female −0.041 (-0.171, 0.089) −0.047 (-0.115, 0.021) −0.072 (-0.151, 0.007) −0.014 (-0.085, 0.057) −0.016 (-0.085, 0.053)
By arsenic metabolism (ratio of urinary arsenic metabolites)
First methylation step (MMA/iAs)
below median −0.025 (-0.107, 0.056) −0.023 (-0.077, 0.017) −0.007 (-0.066, 0.052) −0.009 (-0.056, 0.038) −0.003 (-0.047, 0.041)
above median 0.023 (-0.066, 0.111) −0.005 (-0.050, 0.040) 0.003 (-0.049, 0.056) 0.021 (-0.027, 0.069) 0.008 (-0.040, 0.057)
Second methylation step (DMA/MMA)
below median −0.023 (-0.166, 0.121) −0.057 (-0.137, 0.023) −0.010 (-0.193, -0.006)* −0.019 (-0.098, 0.061) 0.018 (-0.061, 0.098)
above median 0.012 (-0.058, 0.082) −0.007 (-0.044, 0.029) 0.027 (-0.014, 0.069) 0.021 (-0.017, 0.060) 0.001 (-0.036, 0.038)
Abbreviations: CI, confidence interval; iAs, inorganic arsenic; MMA, monomethylarsonic acid; DMA, dimethylarsinic acid.
*p-value < 0.05.
All models adjusted for maternal pre-pregnancy BMI (kg/m2), parity (number), and maternal urinary creatinine (mg/L).
afurther adjusted for fetal sex.
bfurther adjusted for maternal age (years).
cfurther adjusted for maternal smoking.
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chance (Table 3).
In our sensitivity analyses restricted to the 133
mothers with known and reliable estimates of gestational
age from LMP, the Spearman correlation coefficient be-
tween maternal urinary arsenic concentration and HC
Z-score was -0.05, p-value = 0.57. Among just female
fetuses the Spearman correlation coefficient between
urinary arsenic concentration and HC Z-score was -0.09,
p-value = 0.54. In our analyses where we excluded the
16 mothers with multiple ultrasound examinations, asso-
ciations were very similar overall. However, the inverse
association between BPD Z-score and urinary arsenic
concentration among female fetuses became statistically
significant (a 1 μg/L increase in urinary arsenic concen-
tration was associated with a 0.089 (95% CI: 0.170,
0.008) decrease in BPD Z-score).
Discussion
Prior studies have performed information extraction
from pathology and other types of radiography reports;
however, our study is among the first to demonstrate
the utility of information extraction techniques to ac-
curately obtain fetal biometric measurements from
EMRs as assessed during prenatal visits. Our work
clearly demonstrates how additional important health
information (data not originally collected by the study)
can be obtained and used for epidemiologic study.
Validated and automated techniques that can be ap-
plied to EMR data have the distinct advantage of being
able to collect data more efficiently than manual review.This may be particularly of interest to epidemiologists
interested in studying rare outcomes. In our study we
validated a tool using data from only one US medical in-
stitution. Building upon our approach, future work can
further develop and adapt a more universal tool to ex-
tract biometric measurements from a variety of different
structured fetal ultrasound reports (i.e., fetal ultrasound
reports that may be structured differently).
In addition to demonstrating one method of extracting
data from EMRs, we also found that exposure to low
levels arsenic in the US population may be associated
with reduced head growth (measured as HC and BPD)
among female fetuses albeit with limited statistical preci-
sion. Previous studies have used biometric measure-
ments manually extracted from fetal ultrasound reports
to examine the impacts of environmental exposures. For
instance, reduced BPD and HC have been related to ex-
posure to aromatic hydrocarbons [22,23] and maternal
factors such as both passive and active exposure to
smoke [42-44] and maternal occupational exposure to
air pollutants related to impaired fetal most growth mea-
sures [45]. The only prior study of arsenic exposure and
intrauterine growth to our knowledge was in highly
exposed population and found fetal growth effects in
sex-specific manner – arsenic exposure was weakly asso-
ciated with reduced EFW in males [10].
In our relatively small sample we found suggestive in-
verse associations with in utero arsenic exposure (mea-
sured by maternal urinary arsenic concentration) and
HC Z-score (rs = −0.08, p-value = 0.21). Future work in
larger study populations are required to make more
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associations between in utero arsenic exposure and fetal
growth in sex-dependent manner. Most notably, we
found an inverse association between in utero exposure
to arsenic and head growth (both HC and BPD) among
female fetuses. This is a potentially important finding
and suggests that maternal exposure to low-level arsenic
may be directly related to changes in fetal growth.
While the long-term health effects of reduced in utero
growth remain unclear, there is emerging evidence that
intrauterine growth may be related to birth outcomes
and health later in life [46]. For instance, early fetal
growth has been associated with two important birth
outcomes: birth weight and gestational age of delivery
[47]. Early life head growth in particular has been associ-
ated with a number of different early childhood health
outcomes including motor, cognitive, and other neuro-
developmental effects [48-51]. Furthermore, a recent
large study has found growth during the first trimester
(as measured by crown to rump fetal length) to be asso-
ciated with cardiovascular outcomes later in childhood
[52]. Collectively, mounting evidence does suggest that
early growth is an important predictor of a variety of
downstream health effects.
In regards to our preliminary analyses of in utero ar-
senic exposure and fetal growth, there are a number of
important limitations of our study that must be ac-
knowledged. First, our cross-sectional analysis consisted
of only 223 mothers who received prenatal care at a
medical institution. While even among this small sample
we did find suggestive associations, our study was statis-
tically underpowered and therefore our findings are not
conclusive (our study was powered at 0.32 to detect an
association of -0.1 and 0.85 to detect an association of
-0.2). Moreover, the generalizability of our findings is
limited to mothers who receive prenatal medical care
(effects may differ among mothers who do not receive
prenatal care as in other parts of the world). Second,
standardized equations to calculate gestational-age spe-
cific Z-scores in US populations have not been pub-
lished. Therefore, based on fit with our data, we selected
reference populations from England and the Netherlands
for our study. Although these reference populations ap-
peared to closely resemble our study population we can-
not rule out potential misclassification. Third, in 90 out
of 223 mothers in our study, gestational age was esti-
mated by the ultrasound examination itself. Although
this could have affected the associations we observed, in
our sensitivity analysis restricted to mothers with known
LMP, our finding of an inverse association between HC
and in utero exposure changed only slightly. Fourth, as
our study examined associations between low levels of
arsenic and fetal growth a considerable number of ar-
senic species in the maternal urine were below the limitof detection requiring assignment of values. Considering
the high number of samples below the limit of detection
particularly for arsenate and arsenite, this could have
misclassified the total arsenic exposure at very low levels
thus driving observed associations towards the null.
Lastly, our study is a cross-sectional analysis with fetal
biometric measurements taken between 18 and 22 weeks
gestation and in utero arsenic exposure taken between
approximately 24 and 28 weeks of gestation. Therefore
our study is not designed to evaluate a true cause-effect
relationship; however, we suspect reverse causality to be
unlikely (i.e., that reduced growth causes higher arsenic
exposure). Further, the chronological gap in time be-
tween fetal growth and estimation of in utero arsenic ex-
posure (by maternal urinary arsenic concentration which
is a measure of recent exposure) could have contributed
to misclassification. Nevertheless, there is evidence that
urinary arsenic concentration is a fairly consistent esti-
mate of total arsenic exposure over long periods of time
[53,54].
Despite these limitations, our study offers two important
contributions to the literature. First, we have demon-
strated that automated techniques can be used to extract
biometric measurements successfully from EMRs. Second,
our preliminary analyses offer important insights into
the potential relationship between exposure to rela-
tively low levels of arsenic and fetal growth in US popu-
lations. Future work is required to establish more
conclusive findings and further evaluate the potential
health effects related to in utero arsenic exposure.
Additional file
Additional file 1: Figure S1. Estimated fetal weight (A), head
circumference (B), biparietal diameter (C), abdominal circumference
(D), and femur length (E) across week of gestation (18 to 40 weeks)
compared to reference population. In all panels, solid black line represents
the mean of the reference population and dashed black lines represent the
5th and 95th percentiles of the reference population.
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